EGFR and cancer: We evaluated whether the expression of TAGLN2 affects the chemosensitivity of other chemodrugs, including anti-metabolites (5-FU), platinum-based anti-cancer drugs (cisplatin, oxaliplatin, and carboplatin), topoisomerase inhibitors (irinotecan and etoposide), an EGFR inhibitor (erlotinib), and cMET inhibitors (crizotinib and savolitinib) in SNU1196/GR cells.